CoChat

Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials

Horn, Deborah B., Kahan, Scott, Batterham, Rachel L., Cao, Dachuang, Lee, Clare J., Murphy, Madhumita, Gonsahn‐Bollie, Sylvia, Chigutsa, Farai, Stefanski, Adam, Dunn, Julia P. · 2025 · Clinical Obesity
Cited by 25

The DOI matches its Crossref record, with a small difference in title or year; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Summary: The rate of weight reduction during obesity treatment declines over time and eventually reaches a weight plateau. We investigated factors associated with time to weight plateau (TTWP) in tirzepatide‐treated participants with obesity or overweight in a post‐hoc analysis of SURMOUNT‐1 and SURMOUNT‐4 trials. Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT‐1; week 88 SURMOUNT‐4) were included. Weight plateau was defined as a weight change <5% over a 12‐week interval and all subsequent 12‐week intervals. TTWP was time from randomization to the start of the first 12‐week interval. Association between baseline characteristics and TTWP was assessed. Overall, 1438 participants in SURMOUNT‐1 and 259 in SURMOUNT‐4 were included. Across BMI categories (overweight, class I, II, and III), median TTWP in SURMOUNT‐1 was 24.3, 26.0, 36.1, and 36.1 weeks, respectively ( p <.05, class II and III vs. overweight). By week 72, 90.2%, 88.9%, 87.6%, and 87.8% of participants in SURMOUNT‐1 had reached a weight plateau across respective BMI categories [Correction added on 22 January 2025, after first online publication: The “72%” has been changed to “72” in this version.]. Higher doses of tirzepatide (10/15 mg), younger age, and female sex were more likely to reach a weight plateau later. Results in SURMOUNT‐4 were similar. In this post‐hoc analysis, most participants reached a weight plateau by week 72. Higher doses of tirzepatide, younger age, and female sex were associated with a longer TTWP. Further research into modifiers of weight reduction phases with tirzepatide may inform treatment decisions for its use in chronic weight management. Clinical Trial Registration : ClinicalTrials.gov , identifiers NCT04184622 (SURMOUNT‐1) and NCT04660643 (SURMOUNT‐4), available at http://www.clinicaltrials.gov/

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cob.12734

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Mean BMI over time by baseline BMI category in SURMOUNT‐1. *p <.05 for comparison of mean BMI of the given BMI category versus BMI category ≥27–<30 kg/m2 (overweight) based on analysis of variance (ANOVA) model. BMI, body mass index.
FIGURE 1 Mean BMI over time by baseline BMI category in SURMOUNT‐1. *p <.05 for comparison of mean BMI of the given BMI category versus BMI category ≥27–<30 kg/m2 (overweight) based on analysis of variance (ANOVA) model. BMI, body mass index.CC BY-NC-ND · PubMed Central
FIGURE 2 Panel (A) shows the percent weight change over 12‐week intervals by BMI category. Panel (B) shows the proportion of participants reaching <5% weight plateau in SURMOUNT‐1. *p <.05 for comparison with BMI category ≥27–<30 kg/m2 (overweight).
FIGURE 2 Panel (A) shows the percent weight change over 12‐week intervals by BMI category. Panel (B) shows the proportion of participants reaching <5% weight plateau in SURMOUNT‐1. *p <.05 for comparison with BMI category ≥27–<30 kg/m2 (overweight).CC BY-NC-ND · PubMed Central
FIGURE 3 Average increase in mean time to weight plateau between subgroups in SURMOUNT‐1. ***p <.001, *p <.05. aAge comparison of older versus younger by 10 years. TZP, tirzepatide.
FIGURE 3 Average increase in mean time to weight plateau between subgroups in SURMOUNT‐1. ***p <.001, *p <.05. aAge comparison of older versus younger by 10 years. TZP, tirzepatide.CC BY-NC-ND · PubMed Central
FIGURE 4 Current and future state of obesity treatment.
FIGURE 4 Current and future state of obesity treatment.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 10

  1. Hall KD, Kahan S. Maintenance of lost weight and long‐term Management of Obesity. Med Clin North Am. 2018; 102(1): 183‐ 197. doi: 10.1016/j.mcna.2017.08.012 29156185 PMC5764193 · DOI · Paper page
  2. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT‐2): a double‐blind, randomised, multicentre, placebo‐controlled, phase 3 trial. Lancet. 2023; 402(10402): 613‐ 626. doi: 10.1016/s0140-6736(23)01200-x 37385275 · DOI · Paper page
  3. MacLean PS, Rothman AJ, Nicastro HL, et al. The accumulating data to optimally predict obesity treatment (ADOPT) Core measures project: rationale and approach. Obesity. 2018; 26(Suppl 2): S6‐ S15. doi: 10.1002/oby.22154 29575780 PMC5973529 · DOI · Paper page
  4. le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity. 2023; 31(1): 96‐ 110. doi: 10.1002/oby.23612 PMC10107501 36478180 · DOI · Paper page
  5. National Academies of Sciences E, and Medicine; Health and Medicine Division; Food and Nutrition Board. Translating Knowledge of Foundational Drivers of Obesity into Practice: Proceedings of a Workshop Series. National Academies Press (US). 2023. 37639520
  6. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes. 2015; 39(8): 1188‐ 1196. doi: 10.1038/ijo.2015.59 PMC4766925 25896063 · DOI · Paper page
  7. van Baak MA, Mariman ECM. Obesity‐induced and weight‐loss‐induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023; 19(11): 655‐ 670. doi: 10.1038/s41574-023-00887-4 37696920 · DOI
  8. Flanagan EW, Spann R, Berry SE, et al. New insights in the mechanisms of weight‐loss maintenance: summary from a Pennington symposium. Obesity. 2023; 31(12): 2895‐ 2908. doi: 10.1002/oby.23905 37845825 PMC10915908 · DOI · Paper page
  9. Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes. 2006; 30(3): 391‐ 399. doi: 10.1038/sj.ijo.0803175 16302013 · DOI · Paper page
  10. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021; 325(14): 1414‐ 1425. doi: 10.1001/jama.2021.3224 33755728 PMC7988425 · DOI · Paper page

Cited by

Metadata

Authors
Horn, D. B., Kahan, S., Batterham, R. L., Cao, D., Lee, C. J., Murphy, M., Gonsahn‐Bollie, S., Chigutsa, F., Stefanski, A., & Dunn, J. P.
Affiliations
  • University of Texas, McGovern Medical School Houston Texas USA
  • George Washington University School of Medicine Washington DC USA
  • Eli Lilly and Company Indianapolis Indiana USA
Venue
Clinical Obesity
Publisher
Wiley
Published
2025-01-12
Volume
15
Issue
3
ISSN
  • 1758-8103
  • 1758-8111
Cited by
25
References
11
Language
en
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.